Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
IRVINE, Calif., March 29, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Kandi Technologies Group, Inc. (“Kandi” or the “Company”) (Nasdaq:KNDI). Investors who purchased or otherwise acquired shares between March 16, 2015 and March 13, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 15, 2017 lead plaintiff motion deadline.
If you purchased shares of Kandi during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Kandi made false and/or misleading statements and/or failed to disclose that: certain areas in the Company’s previously issued financial statements for the years ended December 31, 2015 and 2014, and the first three quarters for the year ended December 31, 2016 required adjustment; Kandi lacked effective internal controls over financial reporting; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On November 14, 2016, the Company announced the abrupt resignation of its CFO Cheng Wang. On March 13, 2017, Kandi filed a Current Report on Form 8-K with the SEC, announcing that the Company would restate previously issued financial statements for the years ended December 31, 2015 and 2014, and the first three quarters for the year ended December 31, 2016.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
